The largest community of pharma leaders

Nautilus Biotechnology Appoints Nick Nelson as Chief Business Officer

SAN CARLOS, Calif. & SEATTLE–()–Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for quantifying the human proteome, today announced the appointment of Nick Nelson as Chief Business Officer. Joining the company on the heels of Nautilus’ recent $76 million series B funding, Mr. Nelson will drive the design and execution of the company’s business development activities, including partnerships, alliances, and community engagement.

“Anyone who’s worked with Nick knows that he is an exceptionally talented leader in the life sciences and biotechnology world,” said Sujal Patel, co-founder and CEO of Nautilus Biotechnology. “His rich business and market development expertise will complement our strong research and development organization to help ensure we maximize our platform’s opportunity to spark a transformation in biomedical research.”

“I’m deeply inspired by the potential I see in Nautilus and am energized by the opportunity to be a part of the team bringing this incredibly novel platform to market,” said Nick Nelson, Chief Business Officer, Nautilus Biotechnology. “I’ve been fortunate to be a part of the genomics revolution, creating entirely new markets and applications enabled by a significant advancement in sequencing technology. Nautilus has all of the elements necessary to lead the next 20-year wave of transformative research and applications in proteomics and advanced data analytics.”

“Nick brings a deep understanding of science and technology and, as importantly, an unwavering dedication to customer and partner success,” said Matt Posard, Founding Principal at Explore DNA, Nautilus Board member, and former SVP & Head of Sales at Illumina. “When I worked closely with Nick at Illumina, his passion and insistence on creating mutually beneficial relationships with customers and partners set him apart. I’m excited to see him bring that same focus and commitment to Nautilus.”

Mr. Nelson has extensive leadership experience with top-tier diagnostics, therapeutics and life science companies. Before joining Nautilus, he was Chief Business Officer at Caris Life Sciences where he led all business development and strategic partnerships, and also led the creation of industry leading products for biopharma and oncology therapeutic development. Prior to Caris, he was Vice President of Commercial and Corporate Development at Trovagene (now Cardiff Oncology), and before that spent 10 years at Illumina in positions spanning R&D, technical service, sales and business management. While at Illumina he held leadership positions in the New and Emerging Markets business where he established partnerships and collaborations enabling high growth genomics businesses. He received his Bachelor of Science degree in Cellular and Molecular Biology from San Diego State University.


Based in San Carlos, CA and Seattle, WA, Nautilus is a biotechnology company whose proteomics platform will deliver superior sensitivity far more quickly, more completely, and less expensively than is currently possible. By breaking through the limitations of existing technologies, and effectively democratizing proteomics, Nautilus will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and usher in a new era of personalized and predictive medicine. Learn more at:


Recent Articles

ONK Therapeutics Closes New Financing and Appoints Chris Nowers as CEO

GALWAY, Ireland--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has raised US$8M in a financing from...

Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab...

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of...

Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

BOCA RATON, Fla.--(BUSINESS WIRE)--Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned...

Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer

OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in...

Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech

BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, today announced that...